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Background/Aims: Proton pump inhibitor-responsive 
esophageal eosinophilia (PPI-REE) is a newly recognized 
form of eosinophilic esophagitis (EoE) that responds to PPI 
therapy. It remains unclear whether PPI-REE represents a 
subphenotype of gastroesophageal reflux disease, a sub-
phenotype of EoE, or its own distinct entity. The aim was to 
evaluate the clinicopathologic features of PPI-REE. Methods: 
Six patients were diagnosed with PPI-REE based on symp-
toms, endoscopic abnormalities, esophageal eosinophilia 
with ≥15 eosinophils/high-power field, and a response to PPI 
treatment. Symptoms and endoscopic and pathological find-
ings were evaluated. Results: The median follow-up duration 
was 12 months. Presenting symptoms included dysphagia, 
heartburn, chest pain, foreign body sensation, acid reflux, 
and sore throat. All patients had typical endoscopic findings 
of EoE such as esophageal rings, linear furrows, nodularity, 
and whitish plaques. Three patients had a concomitant al-
lergic disorder, and one had reflux esophagitis. Four patients 
exhibited elevated serum IgE, and five had positive skin prick 
tests. All patients experienced symptomatic resolution within 
4 weeks and histologic resolution within 8 weeks after start-
ing PPI therapy. There was no symptomatic recurrence. 
Conclusions: PPI therapy induced rapid resolution of symp-
toms and eosinophil counts in patients with PPI-REE. Large-
scale studies with long-term follow-up are warranted. (Gut 
Liver 2016;10:37-41)
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INTRODUCTION
Eosinophilic esophagitis (EoE) is a chronic inflammatory dis-
order characterized by eosinophilic infiltration in the esophagus, 
in which its occurrence has been increasingly recognized in 
Western countries.1,2 However, esophageal eosinophilia is not 
specific for EoE. Esophageal eosinophilic infiltration (EEI) occurs 
in a number of conditions, including infections, drug hypersen-
sitivity, gastroesophageal reflux disease (GERD), celiac disease, 
Crohn’s disease, hypereosinophilic syndrome, connective tissue 
diseases, and graft-versus-host disease.3 Among other condi-
tions, GERD and proton pump inhibitor-responsive esophageal 
eosinophilia (PPI-REE) are common diseases that must be dif-
ferentiated from EoE.3-5
PPI-REE is a newly described disease. It is diagnosed when 
patients have esophageal symptoms and histologic features of 
esophageal eosinophilia but exhibit symptomatic and histologic 
improvement with PPI therapy.3 The first case series of three pe-
diatric patients whose symptoms and eosinophilia resolved with 
PPI treatment was reported by Ngo et al.6 in 2006. 
Retrospective studies have demonstrated that 39% to 71% of 
children and adults with EEI have PPI-REE.7-11 However, there 
have been very few reports regarding PPI-REE in Asian popula-
tions. A recent study from Japan reported that the prevalence of 
EoE and PPI-REE was two (0.01%) and three (0.02%) of 13,634 
patients, respectively, who underwent upper gastrointestinal (GI) 
endoscopy.12 Another Japanese case series of 12 patients with 
EEI reported that after PPI treatment, two patients (28.6%) were 
diagnosed with EoE and five  patients (71.4%) were diagnosed 
with PPI-REE.13 A recent American College of Gastroenterology 
guideline recommends that patients suspected of EoE be given 
PPI treatment to exclude PPI-REE. In addition, the guideline 
recommends additional evaluation, such as ambulatory pH 
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monitoring, to determine whether GERD is the cause of EEI.3 
Despite the increasing recognition of PPI-REE, it is unclear 
whether PPI-REE is a GERD variant, an EoE variant, or an inde-
pendent disease entity. A recent prospective cohort study from 
the United States reported that clinical, endoscopic, and histo-
logic features could not distinguish PPI-REE from EoE before 
a trial using PPI.14 The aim of this study was to investigate the 
clinical, endoscopic, and histologic characteristics of PPI-REE in 
Korean adult patients.
MATERIALS AND METHODS
1. Patients
We reviewed the records of 20 patients diagnosed with EEI at 
four tertiary university hospitals in urban areas between Sep-
tember 2005 and May 2013. The diagnosis cutoff value for EEI 
was defined as a peak of ≥15 eosinophils per high-power field 
(HPF) on esophageal biopsy. Patients were diagnosed with EoE 
if they met these criteria: (1) presence of symptoms related to 
esophageal dysfunction; (2) mucosal eosinophilia in a esopha-
geal biopsy with at least 15 eosinophils per HPF, which persisted 
even after a PPI therapeutic regimen; and (3) absence of other 
causes of esophageal eosinophilia. Patients were diagnosed with 
PPI-REE if they had esophageal symptoms and histologic fea-
tures of esophageal eosinophilia, and resolution of symptoms 
and histologic features after a 2-month course of a PPI thera-
peutic regimen.3 Baseline patient characteristics were recorded, 
including age, gender, and allergic history (e.g., food allergy, 
allergic dermatitis, allergic rhinitis, and asthma). The presence 
of these symptoms was noted: food impaction, dysphagia, 
heartburn, chest pain, and sore throat. The peripheral eosinophil 
count and serum IgE levels were recorded. Endoscopic findings 
of suspected EoE included mucosal rings, linear furrows, white 
exudates, friability, and stricture. When present, reflux esopha-
gitis was diagnosed and graded. Two to four biopsies specimens 
were obtained from the mid and distal esophagus. 
Treatment of EEI consisted of PPI and/or inhaled (fluticasone 
propionate) or oral corticosteroid for 4 to 8 weeks. During PPI 
treatment, patients did not follow the six-food elimination diet. 
This study was approved by the Institutional Review Board of 
Gangnam Severance Hospital, Yonsei University College of 
Medicine (3-2013-0249).
2. Immunohistochemistry
Biopsy specimens obtained from the esophagus of three pa-
tients before and after PPI treatment were used for immunohis-
tochemical staining. We used paraffin-embedded tissue speci-
mens and antihuman CCL26 goat polyclonal antibody (AF653; 
R&D Systems, Minneapolis, MN, USA). 
RESULTS
1. Patient flow and characteristics of subjects with PPI-REE
Of the 20 patients with EEI, 11 (55.0%) did not undergo endo-
scopy at the time of follow-up. After PPI treatment, six (30.0%) 
were diagnosed with PPI-REE and three (15.0%) were diagnosed 
Table 1. Baseline Characteristics of Patients with Proton Pump Inhibitor-Responsive Esophageal Eosinophilia 
Case  
no.
Age,  
yr
Sex Symptom Allergic condition
Peripheral  
eosinophilia, /μL
Serum IgE,  
kIU/L
Skin  
prick test
1 54 F Dysphagia, heartburn, foreign body sense, acid reflux None 130 16 Negative
2 46 M Dysphagia Unknown factor 210 >1,000 Positive
3 19 M Dysphagia, foreign body sense, acid reflux, sore throat Asthma, allergic rhinitis 450 >1,000 Positive
4 24 M Heartburn Food 470 101.9 Positive
5 30 M Heartburn, foreign body sense, acid reflux None   80 269 Positive
6 28 M Dysphagia, chest pain, foreign body sense None 278 147 Positive
F, female; M, male.
Table 2. Endoscopic and Histological Findings of Patients with Proton Pump Inhibitor-Responsive Esophageal Eosinophilia
Case no.
Endoscopic findings
No. of eosinophils, /HPF Concomittent reflux esophagitis
Concentric rings Linear furrows Nodularity Whitish plaque
1 + + - - 36 None
2 + + - - 194 None
3 - + - + >20 None
4 - + - - 21 LA-B
5 + - - - 124 None
6 - + + - >20 None
HPF, high-power field; LA, Los Angeles classification.
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with EoE. The baseline characteristics of patients with PPI-REE 
are shown in Table 1. Five patients with PPI-REE were men 
and one was a woman. Their mean age was 33.5 years (range, 
19 to 43 years). Among six PPI-REE patients, dysphagia was 
present in four (66.7%), heartburn in two (33.3%), chest pain in 
one (16.7%), foreign body sensation in four (66.7%), acid reflux 
in three (50.0%), and sore throat in one (16.7%). Three patients 
with PPI-REE had an allergic history and four had an elevated 
serum IgE. Five patients exhibited positive skin prick tests to 
various allergens. None had peripheral eosinophilia. 
Table 2 presents the endoscopic and histologic findings of the 
patients with PPI-REE. All patients showed typical endoscopic 
findings. Esophageal rings were found in three patients (50.0%), 
linear furrows in five (83.3%), nodularity in one (16.7%), and 
whitish plaques in one (16.7%). Concomittent reflux esophagitis 
corresponding to Los Angeles classification grade B was ob-
served in one (16.7%) patient. The number of infiltrated eosino-
phils ranged from 21 to 194 per HPF. 
The results of treatment outcomes of patients with PPI-
REE are presented in Table 3. Six patients with PPI-REE were 
received a standard dose of PPI once daily. All patients had 
resolution of symptoms within 4 weeks after PPI therapy 
and resolution of histologic changes within 8 weeks after PPI 
therapy. Endoscopic findings changed diversely after PPI treat-
ment. There was no symptomatic recurrence during follow-up. 
The median follow-up duration was 12 months (range, 2 to 61 
months).
2. Immunohistochemistry for eotaxin-3
Esophageal tissue of three patients with PPI-REE was stained 
for eotaxin-3 before and after PPI treatment. Eotaxin-3 was 
expressed in the esophagus of patients with PPI-REE before 
PPI treatment; however, it was expressed only weakly after PPI 
treatment (Fig. 1). 
Table 3. Treatment Outcomes of Patients with Proton Pump Inhibitor-Responsive Esophageal Eosinophilia
Case no. Interval of follow up endoscopy, mo Therapeutic agents* Esophageal eosinophilia Symptom resolution
1 2 Rabeprazole Disappearance Yes
2 3 Esomeprazole Decrease Yes
3 2 Pantoprazole Disappearance Yes
4 3 Esomeprazole Disappearance Yes
5 2 Esomeprazole Decrease Yes
6 2 Pantoprazole Decrease Yes
*Six patients with proton pump inhibitor-responsive esophageal eosinophilia received a standard dose of proton pump inhibitor once daily.
A
B
Fig. 1. Immunohistochemical staining of eotaxin-3 in proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) (×400). Eotaxin-3 was 
fully expressed in the esophagus of patients with PPI-REE before PPI treatment (A) and was expressed only weakly after PPI treatment (B).
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DISCUSSION
The concept of PPI-REE was recently recognized. However, 
the clinicopathologic characteristics and pathogenesis of PPI-
REE are not well understood. Dellon et al.14 reported that 24 of 
66 patients (36.4%) with EEI had PPI-REE after a PPI trial and 
that no clinical or endoscopic findings independently distin-
guished PPI-REE from EoE. It remains uncertain whether PPI-
REE is a subtype of EoE, a subtype of GERD, or an independent 
disease entity. It also remains unknown whether some patients 
with PPI-REE will eventually be categorized as belonging to 
a subtype of EoE over time. One case report showed that four 
pediatric patients with transient PPI-REE eventually developed 
recurrent endoscopic abnormalities and panesophageal eosino-
philia despite continued PPI treatment. The authors thereby rec-
ommended that patients with PPI-REE be monitored closely for 
evidence of EoE because PPI-REE represented a subphenotype 
of EoE.15 
There have been many studies of PPI-REE from Western 
countries.7-11 However, there have been few reports regarding 
PPI-REE in Asia and no previous report about the incidence or 
clinicopathologic characteristics of PPI-REE in Korea. A recent 
Japanese multicenter study demonstrated that the prevalence of 
EEI was seven (0.05%) of 13,634 Japanese patients who under-
went upper GI endoscopy. Among these seven patients, three 
(0.02%) had PPI-REE. Another study from Japan reported that 
four of 23,346 patients who underwent routine GI endoscopy in 
17 institutions were endoscopically and histologically diagnosed 
with EoE. Among these four patients, two had a partial symp-
tomatic response after PPI administration.16 Reasons for the 
low prevalence of PPI-REE in Asia have not been established, 
although ethnic differences might be an important factor. And, 
there was no clinicopathologic characteristics independently 
distinguished PPI-REE from EoE. In this study, the clinical or 
endoscopic findings were similar between the patients with 
PPI-REE and EoE. And, the clinicopathologic characteristics of 
patients with PPI-REE in Korea were comparable with previous 
Western reports.
The symptomatic and histologic responses to PPI treatment 
have been attributed to several mechanisms. First, some patients 
with PPI-REE may have concomitant GERD. Acid suppression 
may therefore reduce the symptoms and eosinophilic infiltration 
of patients with PPI-REE. And, PPI had an effect to attenuate 
the permeability of the esophageal wall and thereby decrease 
antigen exposure.17,18 Second, it is possible that PPIs have direct 
eosinophil-reducing and anti-inflammatory effects independent 
of their effect on gastric acid secretion.19-21 Others have sug-
gested that PPI may decrease eosinophil degranulation and im-
prove symptoms of patients with EoE despite the persistence of 
eosinophilic inflammation.22 
Eotaxin-3 is a potent eosinophil chemoattractant. Previ-
ous reports have indicated that patients with EoE have greater 
esophageal mucosal expression of eotaxin-3 mRNA and exhibit 
profound upregulation of the eotaxin-3 gene in esophageal mu-
cosal biopsy specimens.23,24 Therefore, it has been suggested that 
PPI may improve PPI-REE by a mechanism involving esopha-
geal expression of eotaxin-3 in EoE. Zhang et al.20 and Cheng et 
al.21 demonstrated that PPI blocks eotaxin-3 expression. Recent 
data (available only in abstract form) reported that eotaxin-3 
was reduced in PPI-REE patients similar to the decrease noted 
in EoE patients after steroid treatment.25 Although we performed 
immunohistochemistry staining in only three patients, we found 
similar results: eotaxin-3 was expressed in the esophagus of 
patients with PPI-REE before PPI treatment, but only weakly 
expressed after PPI treatment. 
Although this retrospective study was limited by the small 
number of patients with PPI-REE and the variable number and 
sites of the esophageal biopsies, this is the first study to report 
the clinicopathologic characteristics of patients with PPI-REE in 
Korea. And, the clinicopathologic characteristics of patients with 
PPI-REE in Korea were similar in Western. A prospective, mul-
ticenter study examining the prevalence and clinicopathologic 
characteristics of PPI-REE in this patient population is required.
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